Non hdl cholesterol

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Non-HDL Cholesterol and Cardiovascular Disease Risk

Non-HDL cholesterol (non-HDL-C) includes all cholesterol carried by atherogenic lipoproteins, such as LDL, VLDL, IDL, and lipoprotein(a), except for HDL. Research consistently shows that non-HDL-C is a strong predictor of atherosclerotic cardiovascular disease (ASCVD) risk, often outperforming LDL cholesterol (LDL-C) alone in identifying individuals at risk for cardiovascular events, especially in those with metabolic disorders, diabetes, or high triglycerides Valaperta2024Hsia2003Raja2023+6 MORE.

Non-HDL Cholesterol vs. LDL Cholesterol: Predictive Value

Multiple large studies and reviews have found that non-HDL-C is better than LDL-C at predicting major adverse cardiovascular events (MACE) and long-term coronary heart disease (CHD) mortality Valaperta2024Raja2023Ito2016+4 MORE. This is because non-HDL-C captures the cholesterol content of all atherogenic particles, not just LDL, making it especially useful in patients with high triglycerides or combined dyslipidemia Hsia2003Raja2023Su2019+1 MORE. For example, individuals with normal LDL-C but elevated non-HDL-C still have a higher risk of ASCVD events, highlighting the added value of non-HDL-C in risk assessment Valaperta2024Wu2023.

Non-HDL Cholesterol in Guidelines and Clinical Practice

Current international guidelines recommend non-HDL-C as a secondary target for lipid management, and some suggest it could become a co-primary or even primary goal, especially in high-risk populations Valaperta2024Raja2023Su2019+3 MORE. Non-HDL-C is easy to calculate from a standard lipid profile and does not require fasting, making it practical for routine use Raja2023Ito2016Wu2023+1 MORE. It is particularly valuable for risk stratification in patients on statin therapy, those with obesity, diabetes, or metabolic syndrome, and in non-fasting samples Raja2023Ito2016Su2019+2 MORE.

Long-Term and Population-Based Evidence

Long-term cohort studies show that higher non-HDL-C levels in childhood and early adulthood are linked to increased risk of ASCVD events later in life Brunner2019Wu2023. Population-based research across multiple countries confirms that higher non-HDL-C is associated with a greater lifetime risk of cardiovascular events, and that early reduction of non-HDL-C can significantly lower this risk . These findings support the use of non-HDL-C for both individual and population-level risk assessment and prevention strategies Raja2023Brunner2019.

Non-HDL Cholesterol, ApoB, and Other Markers

While non-HDL-C is a strong risk marker, some experts argue that apolipoprotein B (apoB) is even more precise, as it directly measures the number of atherogenic particles Soran2019Carr2019Langlois2020. ApoB may be especially useful in patients with high triglycerides, diabetes, or very low LDL-C, but it is less widely available and more costly than non-HDL-C Soran2019Carr2019Langlois2020. When apoB testing is not available, non-HDL-C remains a valuable and accessible alternative Carr2019Langlois2020.

Limitations and Considerations

Some researchers caution against replacing LDL-C with non-HDL-C as the sole target in all patients, noting that non-HDL-C is a heterogeneous measure and may not fully capture risk in certain lipid disorders . They suggest that apoB or a combination of markers may provide the most accurate assessment in complex cases Soran2019Carr2019Langlois2020.

Conclusion

Non-HDL cholesterol is a practical, reliable, and superior marker compared to LDL cholesterol for predicting cardiovascular risk in many populations. It is especially useful in patients with high triglycerides, diabetes, or metabolic syndrome, and is recommended as a secondary or co-primary target in current guidelines. While apoB may offer even greater precision in some cases, non-HDL-C remains an important and accessible tool for cardiovascular risk assessment and management Valaperta2024Hsia2003Raja2023+6 MORE.

Sources and full results

Most relevant research papers on this topic

A-224 Non HDL Cholesterol: could be e new cardiovascular disease risk stratification factor?

Non-HDL cholesterol may have a greater power in identifying cardiovascular disease risk than LDL-C, as cholesterol ratios suggest increased risk for patients with LDL-C100 and N-HDL-C>130 mg/dL.

2024·

0citations

·S. Valaperta et al.

Clinical Chemistry·

DOI

Non-HDL cholesterol: into the spotlight.

Non-HDL cholesterol is a key index in assessing coronary heart disease risk in patients with type 2 diabetes, but its role in predicting CHD risk remains controversial.

Rigorous Journal

2003·

46citations

·S. Hsia

Diabetes care·

DOI

Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.

Non-HDL-cholesterol is an independent risk factor and predictor for atherosclerotic cardiovascular diseases, making it a valuable secondary goal in dyslipidemia management.

Literature ReviewHighly Cited

2023·

143citations

·Vikrama Raja et al.

Atherosclerosis·

DOI

Relationship between non-high-density lipoprotein cholesterol and the long-term mortality of cardiovascular diseases: NIPPON DATA 90.

Non-HDL cholesterol levels are significantly associated with future mortality from coronary heart disease, but not stroke, in the general Japanese population.

Observational StudyRigorous Journal

2016·

29citations

·Takahiro Ito et al.

International journal of cardiology·

DOI

Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol

Non-HDL-C is a better predictor of major adverse cardiovascular events than LDL-C, and should be a primary lipid management target for coronary heart disease patients.

Literature ReviewRigorous Journal

2019·

56citations

·X. Su et al.

Lipids in Health and Disease·

DOI

Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia.

Non-HDL cholesterol should not replace LDL cholesterol in managing hyperlipidaemia, as it is heterogeneous and unsuitable for lipid-lowering treatment.

2019·

10citations

·H. Soran et al.

Current Opinion in Lipidology·

DOI

Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

A 50% reduction in non-HDL cholesterol levels is associated with a reduced risk of cardiovascular disease events by the age of 75, with greater benefits when cholesterol levels are reduced earlier.

Observational StudyRigorous JournalHighly Cited

2019·

228citations

·F. Brunner et al.

Lancet (London, England)·

DOI

Childhood non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events

Childhood non-HDL-C and LDL-C levels are associated with adult atherosclerotic cardiovascular events, but non-HDL-C is better at predicting adult events than LDL-C.

Observational Study

2023·

40citations

·Feitong Wu et al.

Circulation·

DOI

Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.

Non-HDL-cholesterol and apolipoprotein B are more accurate than LDL-cholesterol in predicting atherosclerotic cardiovascular disease risk, making them secondary targets in some treatment guidelines.

Literature ReviewHighly Cited

2019·

161citations

·Stuart S Carr et al.

Pathology·

DOI

Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?

ApoB is a more accurate marker of cardiovascular risk than non-HDL cholesterol, especially in patients with mild-to-moderate hypertriglyceridemia, diabetes, obesity, or metabolic syndrome.

2020·

54citations

·M. Langlois et al.

Current Cardiology Reports·

DOI

Try another search

solar energy in plants

chatbot applications in education

causes of persistent sore throat

diet and nutrition

effect in scientific research

planetary lander missions